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血糖値は164 mg/dL であり，SF 投与中の平均
血糖値178 mg/dL に比べ有意に (P=0.001) 低値
でした。最高血糖値も MHN-01（PF）投与中
















































１）Nakajima M, Irimura T, Di Ferrante D, Di Ferrante N, 
Nicolson GL. Heparan sulfate degradation: relation to 
tumor invasive and metastatic properties of mouse B16 
melanoma sublines. Science 220: 611-613, 1983
２）Uno F, Fujiwara T, Takata Y, Ohtani S, Katsuda K, 
図10　プレアルブミン値は対照群との間に有意差がなかった（文献23から転載・改変）。
Takaoka M, Ohkawa T, Naomoto Y, Nakajima M, Tanaka 
N: Antisense-mediated suppression of human heparanase 
gene expression inhibits pleural dissemination of human 
cancer cells. Cancer Res 61: 7855-7860, 2001
３）Takaoka M, Naomoto Y, Ohkawa T, et al.: Heparanase 
expression correlates with invasion and poor prognosis 
in gastric cancers. Lab Invest 83: 613-622, 2003
４）Ohkawa T, Naomoto Y, Takaoka M, et al.: Localization 
of heparanase in esophageal cancer cells: respective 
roles in prognosis and differentiation. Lab Invest 84: 
1289-1304, 2004
５）Nagatsuka H, Siar CH, Tsujigiwa H, Naomoto Y, Han 
PP, Gunduz M, Sugahara T, Sasaki A, Nakajima M: 
Heparanase and cyclooxygenase-2 gene and protein 
expressions during progression of oral epithelial 
dysplasia to carcinoma. Ann Diagn Pathol 16: 354-361, 
2012. doi: 10. 1016/j. anndiagpath. 2012. 02. 004
６）Okawa T, Naomoto Y, Nobuhisa T, et al.: Heparanase is 
involved in angiogenesis in esophageal cancer through 
induction of cyclooxygenase-2. Clin Cancer Res 11: 
7995-8005, 2005
７）Naomoto Y, Takaoka M, Okawa T, Nobuhisa T, Gunduz 
M, Tanaka N: The role of heparanase in gastrointestinal 
cancer (Reviw). Oncol Rep 14: 3-8, 2005
８）Nagatsuka H, Han PP, Tsujigiwa H, Siar CH, Gunduz 
M, Sugahara T, Sasaki A, Nakajima M, Naomoto Y, 
9猶本：アカデミアと私
Nagai N: Heparanase gene and protein expression in 
ameloblastoma: possible role in local invasion of tumor 
cells. Oral Oncol 41: 542-548, 2005
９）Nobuhisa T, Naomoto Y, Takaoka M, et al.: Emergence 
of nuclear heparanase induces differentiation of human 
mammary cancer cells. Biochem Biophys Res Commun 
331: 175-180, 2005
10）Nobuhisa T, Naomoto Y, Ohkawa T, et al.: Heparanase 
expression correlates with malignant potential in human 
colon cancer. J Cancer Res Clin Oncol 131: 229-237, 
2005
11）Kobayashi M, Naomoto Y, Nobuhisa T, et al. : 
Heparanase regulates  esophageal  kerat inocyte 
differentiation through nuclear translocation and heparan 
sulfate cleavage. Differentiation 74: 235-243, 2006
12）Imada T, Matsuoka J, Nobuhisa T, et al.: COX-2 
induction by heparanase in the progression of breast 
cancer. Int J Mol Med 17: 221-228, 2006
13）Ohtawa Y, Naomoto Y, Shirakawa Y, et al.: The close 
relationship between heparanase and cyclooxygenase-2 
expressions in signet-ring cell carcinoma of the stomach 
Hum Pathol 37: 1145-1152, 2006
14）Katase N, Nagatsuka H, Tsujigiwa H, Gunduz M, 
Tamamura R, Pwint HP, Rivera RS, Nakajima M, 
Naomoto Y, Nagai N. Analysis of the neoplastic nature 
and biological potential of sporadic and nevoid basal 
cell carcinoma syndrome-associated keratocystic 
odontogenic tumor. J Oral Pathol Med. 36: 550-554, 
2007
15）Nobuhisa T, Naomoto Y, Okawa T, et al.: Translocation 
of heparanase into nucleus results in cell differentiation. 
Cancer Sci 98: 535-540, 2007
16）Naomoto Y, Gunduz M, Takaoka M, et al.: Heparanase 
promotes angiogenesis through Cox-2 and HIF1alpha. 
Med Hypotheses 68: 162-165, 2007
17）Rivera RS, Nagatsuka H, Siar CH, et al.: Heparanase 
and vascular endothelial growth factor expression in the 
progression of oral mucosal melanoma. Oncol Rep 2008; 
19: 657-661, 2008
18）Sonoda R, Naomoto Y, Shirakawa Y, et al.: Preferential 
up-regulation of heparanase and cyclooxygenase-2 in 
carcinogenesis of Barrett's oesophagus and intestinal-
type gastric carcinoma. Histopatholog. 57: 90-100, 2010 
doi: 10. 1111/j. 1365-2559. 2010. 03594. x.
19）秋山 洋，鶴丸昌彦，小野由雅，宇田川晴司，梶山
美明．迷走神経温存・食道抜去による食道再建術．
日気食会報 44: 96-98, 1993
20）Ando N, Shinozawa Y, Ikehata Y. Postoperative 
nutritional status in patients with esophageal carcinoma. 
In:, Disease of the esophagus. Vol 1. Malignant diseases 
(Ferguson MK, Little AG, Skinner DB, eds).  Mount 
Kisco, NY: Furuta Publishing Company Inc. 1990, pp. 
261-269
21）Yamada E, Shirakawa Y, Yamatsuji T, et al.: Jejunal 
interposition reconstruction with a stomach preserving 
esophagectomy improves postoperative weight loss and 
reflux symptoms for esophageal cancer patients. J Surg 
Res 178: 700-707, 2012 doi: 10. 1016/j. jss. 2012. 07. 
057.
22）Egi M, Toda Y, Katayama H, Yokoyama M, Morita 
K, Arai H, Yamatsuji T, Bailey M, Naomoto Y. Safer 
glycemic control using isomaltulose-based enteral 
formula: a pilot randomized crossover trial. J Crit Cara 
25: 90-96, 2010
23）Fujiwara T, Naomoto Y, Motoki T, et al.: Effects 
of a novel palatinose based enteral formula (MHN-
01)　carbohydrate-adjusted fluid diet in improving the 
metabolism of carbohydrates andlipids in patients with 
esophageal cancer complicated by diabetes mellitus. J 
Surg Res 138: 231-240, 2007

